A randomized, double-blind, placebo-controlled multicenter phase II study of the COX-2 inhibitor apricoxib (A) in combination with either docetaxel (doc) or pemetrexed (pem) in advanced non-small cell lung cancer (NSCLC) patients (pts) selected by urinary PGE-m suppression.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Rush University Medical Center, Providence Portland Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Massachusetts General Hospital, Abramson Cancer Center, University of Pennsylvania, Weill Cornell Medicine, Stony Brook University, West Virginia University, West Virginia University Hospitals
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2599218749